Your supply chain has no inbox

The thing every peptide clinic has been waiting eighteen months for moved this week. It moved to a desk at the White House, with no deadline, no published text and no list of which peptides it covers.

Then: a fourth Texas pharmacy recalls glutathione, a tirzepatide recall that was never announced to anyone except the customers who bought it, and the twenty-minute fix that connects all three.

1. FDA's interim peptide policy is now at the White House. That is not the same as a green light, and the difference is where clinics get hurt. On October 14, HHS and FDA submitted a document titled “Interim Access Policy for Compounding Using Certain Peptides” to the Office of Information and Regulatory Affairs for review. The public record is thin and worth reading literally: RIN 0910-ZD94, agency HHS/FDA, stage “Notice”, received October 14, 2026, legal deadline “None”, status “Pending Review” (reginfo.gov, RIN 0910-ZD94). Reporting describes it as enforcement discretion — FDA signalling it does not intend to act against 503A pharmacies compounding certain peptides for individual patients under set conditions (Becker’s; Alliance for Pharmacy Compounding). Three things are not true yet, and all three are being said out loud by sales reps right now: the text is not public, no official covered-peptide list exists (BPC-157 appears only in anonymous-source reporting), and the 503A bulks list is unchanged with no Federal Register rule on these peptides. What it means for your clinic: your legal exposure today is identical to your exposure last Tuesday. Nothing has been permitted. The two words to hold onto are “Notice” and “None” — this is styled as a notice rather than a rule, and OMB has no deadline to act, which means it can sit there through Q1 or longer. So: do not pre-sell. Do not let a patient hear “it’s approved now” or “it’s approved in a few weeks” from anyone in your building, and if a compounder’s rep has told you otherwise, get it in writing and watch what happens. The clinics that will take the damage here are the ones that build a peptide line in November against a policy that publishes in March with conditions they can’t meet.

2. A fourth Texas pharmacy recalled glutathione — and this one wasn’t an ingredient problem, it was a route problem. On October 1, Greenwich Rx of Tomball, Texas voluntarily recalled ten lots of Glutathione Injection 200 mg/mL in 10 mL multidose vials over potential elevated endotoxin levels, distributed to patients nationwide June 26 through September 21, with beyond-use dates running to November 12 (FDA, 10/01/2026). FDA’s risk language is unchanged from the earlier three: “reasonable probability that injectable products with elevated endotoxin levels could cause significant medical events including fevers, hypotension, inflammatory reactions, anaphylactic shock and death.” But read the adverse-event line closely — the company received two reports of patients needing emergency department care “following intravenous (IV) administration of a glutathione product that was not formulated for IV use.” That vial was labeled for subcutaneous injection. That makes four Texas pharmacies since August — Victory Medical Center, Austin (08/05), Optimal Balance, Houston (08/19), Centric Compounding, Houston (09/11), and now Greenwich. What it means for your clinic: we told you last issue to ask your pharmacy about ingredient grade. Add a second question, because this recall says the grade wasn’t the only failure point: what route is this vial formulated for, and who in my building decides what goes in the bag? A subcutaneous product going into an IV is not a pharmacy error — it happens at the chair. If your IV menu is built by an aesthetician or a medical assistant working from a recipe card, that is the gap. Put the route on the card, next to the dose.

3. The tirzepatide recall nobody announced. Apothecary Pharma LLC of Cary, North Carolina initiated a nationwide recall on September 24 for lack of assurance of sterility, and FDA classified it Class II on October 8 — meaning use may cause temporary or medically reversible harm. It covers 22 vials of compounded tirzepatide, 18 mg/mL in 4 mL multidose vials (NDC 85091-001-18), lots AP-202622 through AP-202644 excluding AP-202626, plus one vial of NAD+ injection, lot AP-202647, with beyond-use dates in October and November. FDA had already sent the facility a December 2025 warning letter citing “serious deficiencies in your practices for producing drug products intended or expected to be sterile” (Becker’s, 10/2026). Here is the part that matters more than the drug: this recall was communicated by letter to customers, not by public press release. There was no headline on the day it happened. What it means for your clinic: if you are holding tirzepatide or NAD+ from this facility, you found out just now, three and a half weeks after FDA classified it. Check your lots today. Then ask the real question — how would we have found out? If the answer is “the pharmacy would have emailed somebody,” you need to know which somebody, and whether they still work there.

Empower Pharmacy — still silent, now five weeks on. The September 18 warning letter page still carries no posted company response, no closeout letter and no further action as of this check. The fifteen working days FDA asked for elapsed around October 9. As we said last issue: that silence is normal and means nothing in either direction.

Compounded glutathione illnesses — CDC count unchanged. CDC’s page remains last reviewed September 15: over 25 people ill across Texas, Washington, Florida and New York, at least three hospitalized, one in intensive care for shock and abnormal blood clotting. CDC’s instruction is still the blunt one: “Do not administer injectable glutathione products that were compounded using dietary supplement grade ingredients, or products whose ingredient grade cannot be verified with the compounding pharmacy” (CDC).

The 503B GLP-1 rule — no movement. The May 1 proposal not to add semaglutide, tirzepatide or liraglutide to the 503B list (Docket FDA-2018-N-3240) closed comments July 30 and no final determination has published.

PCAC round two — still no date. The second Pharmacy Compounding Advisory Committee meeting on LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF remains scheduled only as “before the end of February 2027” (FDA PCAC page).

Manufacturer DTC pricing — no change. LillyDirect Zepbound ($299–$449/month) and NovoCare Wegovy self-pay (pen $199/month; oral $149/$199/$299) are unchanged over the past seven days.

Look at the three stories above and notice they are the same story. Greenwich Rx: the clinic finds out when a patient is in the emergency department. Apothecary Pharma: the recall goes out by letter, and no headline ever runs. The peptide policy: the loudest voice telling your staff what the rule says is a sales rep with a quota.

In all three, the information existed and was public or semi-public — and it had nowhere to land. Most clinics under twenty staff have no named person who owns inbound supply-chain news. Not because anyone decided that; because it never came up. The pharmacy emails the physician who signed the account three years ago. FDA posts to a page nobody has bookmarked. The MA hears it from a rep.

The fix is embarrassingly small, and it is twenty minutes:

1. Name the owner. One person, by name, owns supply-chain intake. Not “the clinical team.” In a small practice this is usually the office manager, and it should be in their job description in writing.

2. Give it one address. Create a real shared mailbox — [email protected] or similar — and send it to every compounder, wholesaler and distributor you use, in writing, asking them to add it to their recall and notification list. This is the single highest-value email you will send this quarter. A recall letter that reaches a mailbox two people read beats one that reaches a physician who checks that account monthly.

3. Twenty minutes, monthly. Open FDA’s recall page and the warning-letter page, filter to your compounders by name, and write the date you looked on a log. The log is the point. If a patient is ever harmed, “we check monthly and here are the dates” is a fundamentally different conversation than “we would have heard.”

4. Keep a current list of what you actually buy. You cannot check lots against a recall if nobody can say which four pharmacies you order from this month. If producing that list takes more than five minutes, that is your first finding.

None of this is clinical work and none of it requires a consultant. It is an owner's job, it takes one afternoon to stand up, and the first time it catches a recalled lot sitting in your fridge it pays for every hour of attention you have ever given this newsletter.

The Clinic Operator’s Toolkit is close. The flagship is the five-number owner brief we walked through last issue — five default metrics with automatic deltas, a 52-week log, 12 alternate metrics with pull-sources and warning thresholds, a monthly agenda and a worked example — alongside the price-and-margin review, the payment-rail map and the bleed diagnostic. We’re adding a supply-chain-intake one-pager off the lesson above: the vendor-notification email to send, and the monthly log sheet.

Reply “toolkit” and we’ll put you on the founding-price list before it goes public.

Still free from Issue #1: the Processor-vs-EMR Reconciliation Worksheet — the monthly pass that surfaced $58,070 in declined charges at one practice, $41,368 of it never recovered. Download it →

And tell us: who owns supply-chain intake in your clinic — and did you have to think about it? Hit reply. We read everything.

— Devin & Ryan

Who writes this. Devin Casey, MBA and Ryan Arvizo, FNP-C. We operate Revive Medical Care, a cash-pay practice in Phoenix, and BioPeakRx, a LegitScript-certified telehealth platform. That’s why this brief is about compounding supply chains, payment rails and documentation — we run them, and we usually get the decision wrong once before we write it up. When we have a stake in something we mention, we say so in the same sentence. Who we are, and what we own →

The Clinic Brief is business and regulatory information, not legal or medical advice. Talk to qualified healthcare counsel about your specific situation.

Our first paid placement. Worth saying: Wispr Flow is general dictation, not HIPAA-covered and not under a BAA. Fine for vendor emails and policies. Not for anything with a patient's name on it.

Wispr Flow turns your voice into clean, professional text you can send the moment you stop talking. No rough transcription you have to clean up. Actual polished text, ready for email, Slack, or any app.

Speak the way you think. Go on tangents. Change your mind mid-sentence. Flow strips the filler, fixes the grammar, and gives you text that reads like you spent five minutes writing it.

Start flowing free